Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice
ConclusionThe risk of hematological toxicity was significantly higher in the oldest age quartile than in younger patients with mCRPC treated with docetaxel in daily clinical practice.
Source: Drugs and Aging - Category: Geriatrics Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Geriatrics | Hematology | Laboratory Medicine | Netherlands Health | Prostate Cancer | Study | Taxotere | Toxicology